_		_
-	Į	j
	1]
(~~)
ſ	7	Ì
=	_	3
Q	\leqslant	
	T	Ì
Ī	=	ī

JAN 0 3 2002

Under the Paperwork Pa

Das Bellons

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

duction Act of 1995, no persons are required to respond to a

form 1449A/PTQ

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> (use as many sheets as necessary) Sheet 1 of 3

collection of information unless it displays a valid OMB control number.				
Application Number	09/887,465			
Filing Date	June 22, 2001			
First Named Inventor	Edward B. Nelso	onæsal. r		
Group Art Unit	1614	8		
Examiner Name		No.		
Attomey Docket Number	MCP-267	ğ		

U.S. PATENT DOCUME	NTS
--------------------	-----

		U.S. Patent Do	cument			
Examiner Initials	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
كال		5,739,139		Hough et al.	04/14/1998	
		`				
· · · · · · · · · · · · · · · · · · ·						
	1					•

FOREIGN PATENT DOCUMENTS

		Foreign P	Patent Docu	ıment	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. ¹	Office ³	Number ⁴	KindCode ⁵	Applicant of Cited Document mm-dd-yyyy passages or re		passages or relevant figures appear	T ⁶
								<u> </u>
-1								ļ

	Examiner	14-1	Date	12/2 147	_
i	I Sianature I		Considered	14010	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. e Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

uction Act of 1995, no persons are required to respond to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 3

a collection of information unless it displays a valid OMB control number.					
Application Number	09/887,465	Ξ,			
Filing Date	June 22, 2001	20 ·			
First Named Inventor	Edward B. Nelson	etal.			
Group Art Unit	1614	8			
Examiner Name		22			
Attorney Docket Number	MCP-267	8			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²
Initials*	No.1	publisher, city and/or country where published	
		Effect of Acetaminophen on Myeloperoxidase-Nitrite Mediatede Oxidation of LDL, Chou, Tien-min et al., American Heart	
<u> </u>		Association, First conference on arteriosclerosis, Thrombosis, and Vascular Biology, May 20-22; 2000, Omni Interiocken	
		Broomfield/Denver, Colorado (Abstract)	
•		*Acetaminophen Inhibits Fatty Streak Formulation and LDL Oxysterols in Hypercholesterolemic Rabbits*, Addison A. Taylor	
D		et al., Abstracts From the 72 rd Scientific Sessions, Circulation, Vol. 100, Supp. 18, 2 Nov. 1999, p. I-697, Abstract No. 3677	
<u></u>	,	"Acetaminophen blocks atherosclerosis enzyme", C.F. Bergmann, Cardiology Today, July 200	
		"A New Screening Method to Detect Water-soluble Antioxidants: Acetaminophen (Tylenol) and other Phenols React as	
~	1	Antioxidants and Destroy Peroxynitrite-based Luminol-dependent Chemiluminescence", Knox Van Dyke et al., J. Biolumin	
٠ -		Chemilumin, 1998, pgs. 339-348	
	†	"Effect of Nonsteroidal Anti-Inflammatory Drugs on Lipid Peroxidation by Hydroxyl Radical", Yasuhisa Tsujimoto et al., Gen.	
\mathcal{C}	l	Pharmac., Vol. 31, No. 3, 1998, pgs. 405-408	
		Protection against peroxynitirite dependent tyrosine nitration and q,-antiproteinase inactivation by some anti-inflammatory	
D		drugs and by the antibiotic tetracycline, Matthew Whiteman et al., Annals of the Rheumatic Diseases, No. 55, 1996, pgs.	
D	l	383-387 (6 Feb. 1996)	
	 	*Divergent effects of paracetamol on reactive oxygen intermediate and reactive nitrogen intermediate production by U937	
<u>\$</u>		cells", I. Jamil et al., International Journal of Molecular Medicine, No. 4, 1999, pgs 309-312	
	 	*Pretreatment of Mice with Macrophage Inactivators Decreases Acetaminophen Hepatotoxicity and the Formation of reactive	
り		Oxygen and Nitrogen Species, Sherryll L Michael, et al., Hepatology, July 1999, pgs. 186-195	
		*Action of Phenolic Derivatives (Acetaminophen, Salicylate, and 5-Aminosalicylate) as Inhibitors of Membrane Lipid	-
D		Peroxidation and as Peroxyl Radical Scavengers', Teresa C.P. Dinis et al., Archives of Biochemistry and Biophysics, Vol.	
سلا		314, No. 1, November 15, 1994, pgs. 161-169	
		"Effect of Acetaminophen on Oxidative Modification of Human Low Density Lipoprotein", L. Lanningham et al., FASEB	
. ك	i	Journal, April 1994, Abstract No. 2601	
		Paracetamol Catalyzes Myeloperoxidase-Initiated Lipid Oxidation in LDL*, S. Kapiotis, Arteriosclerosis, Thrombosis, and	
6 ~)		Vascular Biology, Vol. 17, No. 11, November 1997, pgs. 2855-2860	
		'Acetaminophen Lowers Fatty Streak Formation and Lipid Oxidation In Hypercholesterolemic Rabbits, Lynette K. Rogers et	
` كاب		al., Free Radical Biology & Medicine, November 1999, Abstract No. 337	
······	 	"Acetaminophen Inhibits Both Chemical And Cell-Mediated Human LDL Oxidation In Vivo and In Vitro", A.A. Taylor et al.,	
		Archives of Pharmacology, July 1998, Abstract P 48,5	
		Protective Effect of Acetaminophen Against Acute Gastric Mucosal Lesions Induced by Ischemia-Reperfusion in the Rat*,	
6			
		Kentaro Nakamoto et al., Pharmacology, 1997, No. 54, pgs. 203-210	
ڪ		"Effect of Acetaminophen on Stress-Induced Gastric Mucosal Lesions in Rats", Hideshi Omura et al., Research	
<u> </u>	ļ	Communications in Molecular Pathology and Pharmacology, Vol. 86, No. 3, December 1994, pgs. 297-310	
		Dorland's Illustrated Medical Dictionary, 25 th Edition, W.B. Saunders, 1981, pgs 143 & 154	
9		*Dissociation of atherogenesis from aortic accumulation of lipid hydro(pero)xides in Watanabe heritable hyperlipidemic	
		rabbits", Paul Witting et al., The Journal of Clinical Investigation, Vol. 104, No. 2, July 1999, pgs. 213-220	
B		Dorland's Pocket Medical Dictionary, 21 st Edition, 1968, pg. 74	
<u> </u>		"Acetaminophen", Barbary Ameer et al, Annals of Internal Medicine, Volume 87, No. 2, August 1977, pgs. 202-209	
سان	1	Paracetamol Inhibits Copper Ion-Induced, Azo Compound-Initiated, and Mononuclear Cell-Mediated Oxidative Modification	
S	1	of LDL", Marit S. Nenseter et al., Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 15, No. 9, September 1995, pgs.	
	ļ	1338-1344	
\ <u>\</u>	1	'A Comparison of the Antiatherogenic effects of Probucol and of a Structural Analogue of Probucol in Low Density	
<u> </u>		Lipoprotein Receptor-deficient Rabbits*, Joachim Fruebis et al., 94 J. Clin. Invest. 392-98 (July 1994)	
(L		The Distribution and Chemical Composition of Ultracentrifugally Separated Lipoproteins in Human serum, Richard J. Havel	
		et al., Richard J. Havel et al., 34 J. Clin. Invest., January 1955, pgs. 1345-1353	
り		Protein Measurement with the Folin Phenol Reagent, Oliver H. Lowry, 193 J. Biol. Chem., May 29, 1951, pgs. 265-275	

Examiner	$U \wedge V$	Date	13 10/22	
Signature		Considered	(VIAOV	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

fuction Act of 1995, no persons are required to respond to

PTO/SB/08A (08-00) TTI
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Re Substitute for Str. 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 3 of 3

a collection of information unless it displays :	a va5d OMB control number.	<u> </u>	•
Application Number	09/887,465	-	1
Filing Date	June 22, 2001	8	
First Named Inventor	Edward B. Nelso	n et al.	
Group Art Unit	1614	8	
Examiner Name		3	
Attorney Docket Number	MCP-267		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
4		"Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits", Br. J. Pharmacol, (1989), No. 98, pgs. 612-618	
7		*Coronary Disease - Atherogenesis: current understanding of the causes of atheroma*, Peter L. Weissberg, Heart No. 83, pgs. 247-252 (2000)	
<u> </u>		"Cytotoxicity of Oxidized LDL to Porcine Acritic Smooth Muscle Cells Is Associated With the Oxysterols 7-Ketocholesterol and 7 Hydroxycholesterol", H. Hughes et al., Arteriosclerosis and Thrombosis, Vol. 14, No. 7, July 1994, pgs. 1177-1185	
10		"Continuous Monitoring of In Vitro Oxidation of Human Low Density Lipoprotein", H. Esterbauer et al., Free Rad. Res. Comms., Vol. 6, No. 1, November 1988, pp. 67-75	
<u></u>		*Decrease in Reactive Amino Groups during Oxidation or endothelial Cell Modification of LDL*, Urs P. Steinbrecher et al., Artheriosclerosis, Vol. 7, No. 2, March/April 1987, pgs. 135-143	
	 		

	Λ	1		
Examiner /	\mathcal{T}		Date	2012/12
Signature (🖳	1		Considered	10/00
77				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.